Table 2.
Summary of the percentage of WHO type I tumors and outcome on overall survival
| Study | Trials included | Patients with WHO type I tumors | OR/HR/RR | ||||
|---|---|---|---|---|---|---|---|
| CCRT | RT | Total (%) | 2 yrs | 3 yrs | 5 yrs | ||
| Huncharek et al [2] 2002* | Al-Sarraf et al [1] | 17/78 | 19/69 | 36/147 (24%) | 0.16 | 0.16 | 0.16 |
| Langendijk et al [3] 2004# | Al-Sarraf et al [1] | 17/78 | 19/69 | 48/781 (6%) | NA | NA | 0.48 |
| Lin et al [8] | 3/141 | 6/143 | |||||
| Chan et al [25] | 2/174 | 1/176 | |||||
| Baujat et al [5] 2006# | Al-Sarraf et al [1] | 17/78 | 19/69 | 41/716 (6%) | NA | NA | 0.60 |
| Chan et al [11] | 2/174 | 1/176 | |||||
| Kwong et al [10] a). Concurrent b). Conc. +AC |
1/53 0/57 |
1/55 0/54 |
|||||
| Our study 2010§ | Kwong et al [10] | 1/110 | 1/55 | 5/1608 (0.31%) | 0.63 | 0.76 | 0.74 |
| Chan et al [11] | 2/174 | 1/176 | |||||
| Wee et al [12] | 0/111 | 0/110 | |||||
| Lee et al [13,18] | 0/172 | 0/176 | |||||
| Zhang et al [14] | 0/59 | 0/56 | |||||
| Lee et al [15,17] | 0/51 | 0/42 | |||||
| Chen et al [16] | 0/158 | 0/158 | |||||
Abbreviations: OR = Odds Ratio, HR = Hazard Ratio, RR = Relative risk (*used OR, #used HR,§used RR in the analysis), NA = Not Available